This ven­ture play­er is plot­ting $200M in new biotech in­vest­ing — and they’re dou­bling down on a start­up-rich strat­e­gy

Eight years ago, the part­ners at Hat­teras Ven­ture Part­ners re­served 20% of their fund for seed-stage plays. The im­pact of se­quenc­ing was spread­ing, dri­ving a trend to­ward more tar­get­ed drugs. And out of that ini­tia­tive came G1 Ther­a­peu­tics $GTHX and a num­ber of oth­er biotechs that have con­tin­ued down their own paths.  

“I think we were prob­a­bly ahead of our time when we launched that,” says Clay Thorp, Hat­teras co-founder and GP. “We’re re­al­ly pleased with the resur­gence in seed and ear­ly-stage com­pa­nies.”

Clay Thorp

Look­ing ahead, Thorp and his col­leagues at Hat­teras now ex­pect to up the ante on star­tups. This morn­ing the ven­ture group is un­veil­ing the launch of fund VI, with the first $94 mil­lion up for grabs in a fund they plan to take to $200 mil­lion. As much as 45% of that will go to the seed port­fo­lio — 6 to 8 com­pa­nies out of a planned 16 to 18 ven­ture-backed plays in to­tal.

Thorp counts him­self as a na­tion­al in­vestor in biotech, but just as they have a spe­cial fo­cus on ear­ly-stage/pre­clin­i­cal com­pa­nies, they al­so like to stay cen­tered on new modal­i­ties like pro­tein degra­da­tion or tar­get­ing RNA with small mol­e­cules, se­lec­tive­ly mak­ing their picks as ri­val biotech groups take shape. And the Durham, NC group al­so likes to act lo­cal­ly when pos­si­ble.

“Gene ther­a­py and gene edit­ing here is quite ripe,” Thorp tells me. “New ar­eas of vec­tors or cap­sids or spe­cial­ly tar­get­ed vec­tors; we think this is a great place for that. Build­ing on AAV, think­ing of oth­er ways to ap­ply that tech­nol­o­gy” through in vi­vo tar­get­ing of im­munother­a­py, I/O and gene edit­ing are all on the ta­ble.

“We’re just on the cusp now of see­ing ways now that tar­get­ing cap­sizes and vec­tors can ad­dress can­cer, im­munol­o­gy,” says the gen­er­al part­ner. So don’t be sur­prised if you see some new in­vest­ments along these lines.

Mike Di­al

Any new seed com­pa­nies that make the grade may well fol­low the same path as G1, which start­ed with $600,000 in pre­clin­i­cal mon­ey and end­ed at $15 mil­lion when it went pub­lic. On the high end, he adds, Hat­teras may go up to $20 or $25 mil­lion in to­tal through the launch and pre-IPO phase.

Thorp con­cedes that it isn’t al­ways easy to find the right CEO and ex­ec­u­tive teams for these star­tups in the South­east. But they’re al­so ready to put head­hunters to work when need­ed to re­cruit. And they’re beef­ing up their own ranks to help fa­cil­i­tate this next wave of in­vest­ments.

Jeff Ter­rell

Mike Di­al and Jeff Ter­rell have been pro­mot­ed to part­ner, while Ben Scrug­gs has been re­cruit­ed as a new as­so­ciate and Kseniya Simp­son joined the fund as an an­a­lyst.

 

 

 


Im­age: Hat­teras Ven­ture Part­ners

Roger Perlmutter. Merck via webcast

'Our lega­cy mat­ter­s': Mer­ck maps out Keytru­da king­dom while spot­light­ing ad­vances in vac­cines, hos­pi­tal care

“You can for the mo­ment stop tak­ing notes. You can put down your pens and your pad. I have no slides. I have no sub­stan­tive da­ta. I have no pitch.”

So be­gan Roger Perl­mut­ter’s brief ap­pear­ance on­stage at Mer­ck’s first in­vestor day in five years, where he dived in­to the com­pa­ny’s his­to­ry dat­ing back to 1933. The first em­ploy­ees at Mer­ck Re­search Lab­o­ra­to­ries, hand­picked by founder George W. Mer­ck, were crit­i­cal to Mer­ck’s abil­i­ty to achieve clin­i­cal and com­mer­cial suc­cess.

Eli Casdin, Casdin Capital

Eli Cas­din backs Codex­is' plat­form tech with $50M eq­ui­ty buy

About a month af­ter Codex­is notched a deal with No­var­tis $NVS, the Cal­i­for­nia com­pa­ny $CDXS on Thurs­day said long-time in­vestor Cas­din Cap­i­tal is putting up $50 mil­lion in a pri­vate place­ment, which puts the New York-based in­vest­ment firm in con­trol of more than 5% of the pro­tein en­gi­neer­ing play­er’s stock.

Eli Cas­din start­ed his epony­mous in­vest­ment firm in 2012 and dates his re­la­tion­ship with Codex­is back to at least a decade. About three years ago, Cas­din Cap­i­tal be­gan in­vest­ing in the in­dus­tri­al biotech com­pa­ny, af­ter it piv­ot­ed its fo­cus to the life sci­ences — un­der the aus­pices of new chief John Nicols — away from the en­er­gy in­dus­try.

How small- to mid-sized biotechs can adopt pa­tient cen­tric­i­ty in their on­col­o­gy tri­als

By Lucy Clos­sick Thom­son, Se­nior Di­rec­tor of On­col­o­gy Pro­ject Man­age­ment, Icon

Clin­i­cal tri­als in on­col­o­gy can be cost­ly and chal­leng­ing to man­age. One fac­tor that could re­duce costs and re­duce bar­ri­ers is har­ness­ing the pa­tient voice in tri­al de­sign to help ac­cel­er­ate pa­tient en­roll­ment. Now is the time to adopt pa­tient-cen­tric strate­gies that not on­ly fo­cus on pa­tient needs, but al­so can main­tain cost ef­fi­cien­cy.

In­vestors pony up $476M for the lat­est round of biotech IPOs to hit the Street

Three biotechs — and a genome se­quenc­ing play­er — have caught the lat­est tide to the Gold Coast of IPOs, round­ing out the first half of 2019 with 23 new drug de­vel­op­ers mak­ing it on Nas­daq.

Most of these com­pa­nies filed their IPOs al­most si­mul­ta­ne­ous­ly, though we’re still wait­ing on word of fel­low class­mate Bridge­Bio’s pric­ing af­ter CEO Neil Ku­mar set the terms at $14 to $16 a share on Mon­day in search of a $240 mil­lion (or so) wind­fall. If he’s suc­cess­ful, that would take the one-week haul past the $700 mil­lion mark, a fresh sign that in­vestors’ en­thu­si­asm for new­ly coined pub­lic biotechs hasn’t cooled.

John Reed at JPM 2019. Jeff Rumans for Endpoints News

Sanofi's John Reed con­tin­ues to re­or­ga­nize R&D, cut­ting 466 jobs while boost­ing can­cer, gene ther­a­py re­search

The R&D reorganization inside Sanofi is continuing, more than a year after the pharma giant brought in John Reed to head the research arm of the Paris-based company.
Endpoints News

Basic subscription required

Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.

The top 10 block­buster drugs in the late-stage pipeline — Eval­u­ate adds 6 new ther­a­pies to heavy-hit­ter list

Vertex comes in for a substantial amount of criticism for its no-holds-barred tactical approach toward wresting the price it wants for its commercial drugs in Europe. But the flip side of that coin is a highly admired R&D and commercial operation that regularly wins kudos from analysts for their ability to engineer greater cash flow from the breakthrough drugs they create.

Both aspects needed for success in this business are on display in the program backing Vertex’s triple for cystic fibrosis. VX-659/VX-445 + Tezacaftor + Ivacaftor — it’s been whittled down to 445 now — was singled out by Evaluate Pharma as the late-stage therapy most likely to win the crown for drug sales in 5 years, with a projected peak revenue forecast of $4.3 billion.

The latest annual list, which you can see here in their latest world preview, includes a roster of some of the most closely watched development programs in biopharma. And Evaluate has added 6 must-watch experimental drugs to the top 10 as drugs fail or go on to a first approval. With apologies to the list maker, I revamped this to rank the top 10 by projected 2024 sales, instead of Evaluate's net present value rankings.

It's how we roll at Endpoints News.

Here is a quick summary of the rest of the top 10:

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.

Robert Forrester, Verastem

Ve­rastem CEO For­rester steps to the ex­it as the board hunts com­mer­cial-savvy ex­ec for the be­lea­guered biotech

Robert For­rester is step­ping down as CEO of Ve­rastem On­col­o­gy $VSTM just 8 months af­ter the com­pa­ny nabbed an ap­proval for du­velis­ib, a PI3K drug with a sto­ried past — and what ap­pears as not much of a fu­ture.

The biotech put out word this morn­ing that For­rester will take an ad­vi­so­ry role with Ve­rastem while COO Dan Pa­ter­son steps up to take charge of the lead­er­ship team and the board looks around for a new CEO.

Ken Frazier appears before the Senate Committee on Finance for a hearing on prescription drug pricing on Capitol Hill in Washington, DC, February 26, 2019. Chris Kleponis for CNP via AP Images

Who’s next in line to suc­ceed Ken Fra­zier as CEO of the Keytru­da-blessed Mer­ck?

When Merck waved off a looming forced retirement for Ken Frazier last September, the board cited flexibility in CEO transition as a key factor in the decision. Having Frazier — who’s also chairman of the company — around beyond his 65th birthday in 2019 would ensure they install the best person at the best time, they said.

The board has evidently begun that process with a clear preference for internal candidates, sources told Bloomberg. CFO Robert Davis, chief marketing officer Michael Nally, and chief commercial officer Frank Clyburn are all in the running, according to an insider.

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,100+ biopharma pros reading Endpoints daily — and it's free.

In starved an­tibi­ot­ic field, Melin­ta soars as FDA grants speedy drug re­view

Such is the state of af­fairs in an­tibi­ot­ic land that the FDA agree­ing to pri­or­i­ty re­view an ap­pli­ca­tion to ex­pand the use of an an­tibi­ot­ic can rock­et up a stock more than two-fold.

On Wednes­day, Melin­ta Ther­a­peu­tics said its ap­proved an­tibi­ot­ic Baxdela had been grant­ed pri­or­i­ty re­view for use in com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia (CAPB). The FDA is ex­pect­ed to make its de­ci­sion by Oc­to­ber 24. Shares of the Con­necti­cut drug­mak­er $ML­NT cat­a­pult­ed, clos­ing up near­ly 224% at $6.41.